Related Reports
Related Tariffs and Trade Reports
• 6APA Non sterile. HS: 2941.10.100
• Ampicillin. HS: 2941.10.200
• Amoxycillin, non sterile. HS: 2941.10.300
• Streptomycin and their derivatives; salts thereof. HS: 2941.20.000
• Erythromycin and its derivatives; salts thereof. HS: 2941.50.000
•Medicaments (excluding goods of heading No. 30.02, heading No. 30.05 or heading No. 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packing retail sale. HS: 30.03
•Medicaments (excluding goods of heading No. 30.02, heading No. 30.05 or heading No. 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packing for retail sale. HS: 30.04

Company News
Indofarma Revises Income Target:
Bisnis Indonesia, page B1 (22-March-2006)
After receiving the order to manufacture Tamiflu from the governemnt, the management of PT Indofarma Tbk has revised its income target this year from Rp720 billion to Rp900 billion. The pharmacy received orders to produce 10-12 million capsules of Tamiflu this year. So far, it has already made 5 million capsules worth Rp80 billion. Although its income may rise, Indofarma predicts that its net profit will not go much higher because the Tamiflu project is not a large order.
KF and Indofarma’s Merger Appraisal Done
Bisnis Indonesia, page B1 (24-February-2006)
The government might merge two pharmacies, PT Kimia Farma Tbk and PT Indofarma Tbk, following the appraisal of the two pharmacies done by PT Mandiri Sekuritas. The merge of the two companies is considered urgent because AFTA will be opened in 2008. By then, the pharmaceutical companies have to be prepared to compete with the foreign companies.

Copyright & Disclaimer
PT. Dataindo Inti Swakarsa makes no representation to any other person with regard to the completeness or accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability (save for liability which cannot be lawfully disclaimed) for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the features, functions, tools, data or information contained herein.Information provided is not financial product advice. This report contains general information only. It is not intended as financial product advice and must not be relied upon as such. You should consider obtaining independent advice tailored to your specific circumstances before making any financial decisions. Copyright in this publication is owned by PT. Dataindo Inti Swakarsa. The publication is sold on the basis that the purchaser agrees not to copy the material contained within it for other than the purchasers own purposes. In the event that the purchaser uses or quotes from the material in this publication - in papers, reports, or opinions prepared for any other person - it is agreed that it will be sourced to: PT. Dataindo Inti Swakarsa

Mrs. Yeliandriani
Indofarma Tbk., PT
Latest Updates 2-July-2024
Major Businessline : Pharmaceutical

PT. Dataindo Inti SwakarsaTelp : (62 - 21) 719 3832
3rd Floor, Gapura Raya BuildingTelp : (62 - 21) 719 3834
Jl. Bangka Raya No. 4, Pela Mampang Email : [email protected]
Jakarta 12720, Indonesia
Selective Member’s Information US $ Select
Position 0.35
Company's Address 0.20
Company's Telephone [3] 0.45
Company's Fax [2] 0.60
Company's Email [2] 0.90
Business Activity 0.30
Selective Member`s Discount Price
US$
To become a Selective Member
Register
Is this person"s information incorect
or out-of-date?
Update Mrs. Yeliandriani’s Information